Navigation Links
Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
Date:11/5/2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced a free Sermo Report titled, "Treatment Options for Gout". The report gathered feedback from physicians to better understand how they currently treat gout and if they would consider using new treatments.  

While many physicians who participated felt that current gout treatments effectively manage acute and suppressed gout flares, 63% confirmed they would utilize new gout medications as they become available. Physicians also listed many different patient types that would benefit from new gout treatments, including recurrent gouty arthritis, tophaceous gout and those resistant to current treatments.

This free Sermo Report polled 114 physicians across multiple specialties, of which 89% see an average of 19 gout patients per month. Many of the respondents also participated in an online discussion regarding various treatment strategies and how they plan to use newly available therapies.

The full reports includes:

  • Key Findings
  • Physician Demographics
  • Discussion Highlights
  • Quantitative and Qualitative Post Analysis

Companies that are in the process of developing or have approved gout treatments include Takeda Pharmaceuticals, Savient Pharmaceuticals, Cardiome Pharma Corp., Regeneron Pharmaceuticals, Ardea Biosciences and Novartis.

To download full results of this free report, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, trends, and other topics of interest. Data for Sermo Reports is
gathered through Sermo Posts, which allow physicians to p
'/>"/>

SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
8. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
9. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... 2014  The board of directors of AbbVie Inc. ... dividend of $0.42 per share.  The ... of record at the close of business on Oct. ... global, research-based biopharmaceutical company formed in 2013 following separation ... expertise, dedicated people and unique approach to innovation to ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... Calif., Sept. 24 Amgen (Nasdaq: AMGN ... PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from ... precaution.  The product that is being recalled may contain ... in most cases. The lamellae result from the interaction ...
... BIOD ) announced today that it will be presenting at the ... Conference, September 28, 2010 at 12:00 pm Eastern time at the ... access a link to the live webcast of the presentation from ... . Replays of the presentation will be available for 90 days. ...
Cached Medicine Technology:Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 2Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 3Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 4Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 5Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 6Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 7Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 8Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 9Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 10Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 11Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 12Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 13Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 14Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 15Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 16Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 17Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 18Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 19Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 20Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 21
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... 20, 2014 Final Cut Pro X ... release of the Information theme for FCPX filmmakers. , “Fun, ... describe the Information theme,” says Christina Austin, CEO of Pixel ... so professional.” , Information features easy to use controls that ... the environment. Change the background color, color of each circle ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4
... disease ... ATLANTA, Nov. 12 One year following the launch of,operations ... Care,Improvement Plus feel their health has maintained or improved, according ... regional,membership. Of those who feel health has improved, 97 percent ...
... give patients a new lease on life. , ... ... back pain are reaching out to an innovative solution helping them ... With facilities in Tampa and Scottsdale, the Laser Spine Institute is ...
... official,breaking news service for North American companies participating in MEDICA,2008, ... The profile of Hokanson follows below., ... 9 /C 02 Web URL : ... the early 1970,s to provide the,instruments for Dr. Eugene Strandness, ...
... Technologies, IntelliFill i.v. robot to ... reduces errors and hospital ... Technologies,Inc., a pioneer in medication error reduction and hospital ... robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the Alegent ...
... survey shows health improvements, disease ... of plan -, SAN ANTONIO, Nov. 12 One ... members of Care Improvement Plus feel,their health has maintained or ... plan,s statewide membership. Of those who,feel health has improved, 97 ...
... Bioef are taking part in a European project the goal ... revolutionise the manner of controlling flu epidemics internationally, thanks to ... from the current 24 hours to a period of between ... number of control points. This research, in which other European ...
Cached Medicine News:Health News:Georgia and South Carolina Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Laser Spine Institute Helping Patients to "Stand Up and Be Free" from Debilitating Back Pain 2Health News:Laser Spine Institute Helping Patients to "Stand Up and Be Free" from Debilitating Back Pain 3Health News:Hokanson Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Design of system that will revolutionize control of influenza epidemics 2
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The SB Charit is a prosthesis system consisting of two endplates made of high quality cobalt chromium alloy with an ultra high molecular weight polyethylene sliding core placed between them....
... The D185 is ... FDA clearance for this ... transcranial motor evoked potentials ... surgical procedures such as ...
Medicine Products: